---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-085434"
form_type: "8-K"
ticker: "CTOR"
cik: "0001851484"
company_name: "CITIUS ONCOLOGY, INC."
filed_at: "2026-08-05T13:28:46+00:00"
generated_at: "2026-08-05T13:30:08.742035+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Citius Oncology reports 78% QoQ increase in new institutions ordering LYMPHIR; vials up 31%

## Summary
- New institutional accounts ordering LYMPHIR increased 78% QoQ; total institutions now 42.
- Vials ordered by institutions rose 31% during quarter ended June 30, 2026.
- LYMPHIR has near-universal payer coverage; initial CTCL market exceeds $400M.
- Company expects >20 additional institutions in current quarter, targeting 100 priority institutions by year-end.
- Wholesaler orders have begun to reflect increased demand; revenue recognized on wholesale orders.

## SEC filing metadata
- accession: 0001213900-26-085434
- form_type: 8-K
- ticker: CTOR
- cik: 0001851484
- company_name: CITIUS ONCOLOGY, INC.
- filed_at: 2026-08-05T13:28:46+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1851484/000121390026085434/0001213900-26-085434-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1851484/000121390026085434/ea0300371-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-085434
- JSON: https://secwatch.observer/filing/0001213900-26-085434.json
- Plain text: https://secwatch.observer/filing/0001213900-26-085434.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.